吸烟与转移性前列腺癌肿瘤遗传学及结局的关联
基于PROMISE临床基因组数据库的回顾性分析纳入2353例可评估体细胞测序的前列腺癌男性,其中当前吸烟者占8%、既往吸烟者占39%、从不吸烟者占52%。当前吸烟与确诊时更差的总体生存相关(99.9个月 vs 137.6个月,HR 1.42,95%CI 1.14-1.77),校正疾病特征后仍显著,并与SPOP、FGFR1、ARID1A特定基因改变相关,但未发现与神经内分泌前列腺癌(NEPC)转化相关。
要点
- 当前吸烟与确诊后更差的总生存独立相关(HR 1.42)。
- 当前吸烟者确诊时更年轻且更易为转移性疾病(M1或N1)。
- 吸烟与SPOP、FGFR1、ARID1A基因改变正相关,但与NEPC转化无关。
核心结论
- 当前吸烟与转移性前列腺癌患者更差的总体生存和前列腺癌特异性生存相关,并与特定肿瘤基因改变相关,但不增加小细胞/NEPC转化风险。
研究设计与样本
- 回顾性分析利用PROMISE临床基因组数据库,纳入2353例具有可评估体细胞肿瘤测序的前列腺癌男性。
- 吸烟暴露按诊断时状态(当前、既往、从不)及包年评估,并与患者特征、肿瘤遗传数据和临床结局关联。
主要发现
- 当前吸烟者更年轻且诊断时更易为转移性疾病(M1或N1),较少接受过局部治疗(均p < 0.001)。
- 当前吸烟与确诊后更差的总生存相关(99.9个月 vs 137.6个月,HR 1.42,95%CI 1.14-1.77),校正疾病特征后仍显著。
- 当前、既往和从不吸烟者之间,初诊时或任何时间点的NEPC比例无差异(p = 0.8)。
- 在转移性雄激素通路调节剂敏感前列腺癌(APMS)患者中,吸烟状态与SPOP(当前15%、既往6.7%、从不3.8%;p = 0.018)、FGFR1(当前10%、既往0.4%、从不1.1%;p = 0.001)和ARID1A(当前5.1%、既往2.2%、从不0.4%;p = 0.035)基因改变正相关。
临床怎么用
- 对转移性前列腺癌患者应强调戒烟,当前吸烟与更差生存独立相关。
- 特定基因改变(SPOP、FGFR1、ARID1A)在吸烟者中更常见,但需进一步验证其临床指导价值。
- 吸烟状态不影响NEPC转化风险,不应据此改变NEPC监测策略。
局限性
- 回顾性研究设计,可能存在残余混杂和选择偏倚。
- 吸烟暴露基于诊断时状态,未报告动态变化。
- 基因关联分析限于APMS亚组,需外部队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Smoking has been associated with increased metastatic prostate cancer mortality, but the mechanisms behind this are largely unknown. We hypothesized that smoking increases the risk of genetic alterations associated with aggressive disease and/or the transformation to neuroendocrine prostate cancer (NEPC). PATIENTS AND METHODS: We utilized the Prostate Cancer Precision Medicine Multi-institutional Collaborative Effort (PROMISE) clinical genomic database for this retrospective analysis. We associated patient characteristics and tumor genetic data with smoking exposure at diagnosis (current, former, never and pack years) and with clinical outcomes, including overall survival (OS) from diagnosis or time to developing metastatic disease and NEPC status. RESULTS: We identified 2353 men with prostate cancer and next generation somatic tumor sequencing evaluable for analysis in PROMISE, including 8% current, 39% former, and 52% never smokers. Current smokers were more likely to be younger and to have metastatic (M1 or N1) disease at diagnosis, and less likely to have prior local therapy (all p < 0.001). Current smoking was associated with worse OS from diagnosis (99.9 mo vs 137.6 mo, HR 1.42, 95% CI 1.14-1.77), which remained significant after adjusting for disease characteristics. We found no difference in the percentage of NEPC at initial diagnosis or at any time between current, former, and never smokers (p = 0.8). We found positive associations between smoking status and genetic alterations in SPOP (current: 15%, former 6.7%, never 3.8%; p = 0.018), FGFR1 (current 10%, former 0.4%, never 1.1% p = 0.001), and ARID1A (current 5.1%, former 2.2%, never 0.4%; p = 0.035) in patients with metastatic androgen pathway modulator sensitive prostate cancer (APMS). CONCLUSION: Active smoking is associated with worse overall and prostate cancer specific survival as compared to never/former smoking and was associated with specific tumor genetic alterations but not small cell/NEPC transformation.
引用
- Choi C, Labriola M, Henderson N, et al. Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 42697914. doi:10.1038/s41391-026-01150-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。